Alongside the age expansion, updated prescribing guidance now clearly identifies immunocompromised individuals as a high-risk group eligible for vaccination. This clarification is expected to help clinicians more easily identify candidates who may derive benefit from preventive immunization.

Addressing RSV Risk Across Adult Populations

RSV is widely recognized as a seasonal respiratory pathogen, but its impact on adults, particularly those with chronic conditions, is often underappreciated. Infection can lead to serious complications, including exacerbations of chronic obstructive pulmonary disease (COPD) and asthma, as well as cardiovascular events such as myocardial infarction and stroke. In severe cases, RSV can result in hospitalization or death.

In Japan, more than 40 million individuals fall within the 18–49 age group. Although typically viewed as lower risk, a significant proportion live with comorbidities that increase their vulnerability to severe RSV outcomes. The expanded approval reflects growing recognition that susceptibility is not limited to older adults.

Clinical Evidence Supporting the Decision

Regulatory approval was underpinned by findings from a phase IIIb immunogenicity study evaluating adults aged 18–49 at increased risk. The results showed that immune responses in this cohort were comparable to those observed in adults aged 60 years and older, meeting non-inferiority criteria. Earlier phase III data had already established the vaccine’s efficacy in preventing RSV-related lower respiratory tract disease in older adults.

Safety findings were consistent across studies, with the most commonly reported adverse events including injection site discomfort, muscle aches, fatigue, joint pain and headache. These reactions were generally temporary and ranged from mild to moderate in severity.

Additional support for the updated labelling came from a phase IIb study in immunocompromised populations, including organ transplant recipients. This trial demonstrated robust immune responses following vaccination, reinforcing the inclusion of these patients among those at heightened risk.

Vaccine Composition and Global Reach

Arexvy is formulated with a recombinant RSV glycoprotein F antigen stabilized in its prefusion conformation, combined with GSK’s proprietary AS01E adjuvant system to enhance immunogenicity. As with all vaccines, individual responses may vary, and use should align with national immunization recommendations.

Globally, the vaccine has achieved broad regulatory uptake. It is approved for older adults in dozens of countries, with several jurisdictions, including the United States and parts of Europe, already extending indications to younger at-risk populations.

Expanding Prevention Strategies

The Japanese approval marks an important step toward more inclusive RSV prevention strategies, recognizing the burden of disease across a wider adult population. By enabling vaccination in younger individuals with underlying health conditions or immune compromise, public health authorities aim to reduce complications and associated healthcare utilization.

GSK continues to pursue regulatory advancements in other regions as it seeks to expand access to RSV prevention worldwide.